Welcome to our dedicated page for Versigent PLC SEC filings (Ticker: VGNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Versigent PLC's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Versigent PLC's regulatory disclosures and financial reporting.
Versigent plc ownership report: BlackRock, Inc. beneficially owns 8,084,933 shares of Versigent common stock, representing 11.4% of the class. The Schedule 13G lists sole voting power for 7,884,995 shares and sole dispositive power for 8,084,933 shares. The filing also notes that iShares Core S&P Small-Cap ETF holds more than 5% of Versigent common stock.
Versigent PLC reported Q1 2026 net sales of $2,212 million, up from $2,024 million a year earlier, but operating income fell to $74 million as restructuring charges of $46 million and Separation costs of $26 million weighed on results.
Net income attributable to Versigent declined to $78 million from $95 million, while a tax benefit produced a (13)% effective tax rate. Cash from operations was $36 million and capital expenditures were $66 million. On April 1, 2026, Aptiv completed the Spin-Off of its Electrical Distribution Systems business, creating Versigent as an independent NYSE-listed company.
To fund a $1,900 million cash distribution to Aptiv and general corporate purposes, Versigent raised substantial long-term financing, including $800 million of 6.125% senior notes due 2031, $800 million of 6.375% senior notes due 2034 and a $500 million Term Loan A Facility under a new $1.35 billion secured Credit Agreement. Total debt rose to $2,141 million, while ordinary shares outstanding were 70,893,660 as of May 1, 2026.
Versigent PLC reported mixed but generally solid first quarter 2026 results and outlined a new capital return strategy. Revenue reached $2,212 million, up 9% year over year, or 3% after adjusting for currency and commodity movements, driven by higher volumes in North America and Asia Pacific.
Net income attributable to Versigent was $78 million, down from $95 million a year earlier, while Adjusted EBITDA edged up to $203 million with a margin of 9.2% versus 9.8% previously. Free cash flow was $(30) million, including $26 million of separation costs related to the spin-off from Aptiv.
For full-year 2026, Versigent reaffirmed guidance, targeting revenue of $9,100–$9,400 million, U.S. GAAP net income of $315–$375 million, Adjusted EBITDA of $950–$1,030 million, operating cash flow of $440–$540 million and free cash flow of $200–$300 million. The board approved a dividend policy aiming for $0.13 per share quarterly and authorized a share repurchase program of up to $250 million, underscoring an emphasis on disciplined capital allocation after the spin-off.
CLARK KEVIN P reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC director Kevin P. Clark reported receiving a grant of 5,168 Ordinary Shares on April 22, 2026, at no cost. After this award, he directly holds 247,571 Ordinary Shares. This total includes 242,403 shares he received on April 1, 2026, in a pro rata distribution from Aptiv PLC.
Vinci Sharon reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC Chief People Officer Vinci Sharon received a grant of 18,617 Ordinary Shares as compensation. The award was recorded at a price of $0.0000 per share, indicating it was not an open-market purchase. Following this grant, Sharon directly holds a total of 61,474 Ordinary Shares.
Versigent PLC chief legal officer and secretary Janis N. Acosta reported receiving two equity awards of the company’s Ordinary Shares. On April 22, 2026, she acquired 21,254 Ordinary Shares at $0.00 per share in a grant classified as a “grant, award, or other acquisition.” Following this grant, her reported direct holdings in that line were 39,871 shares.
On the same date, she received a second grant of 18,617 Ordinary Shares, also at $0.00 per share, with that line showing 18,617 shares held directly after the transaction. These transactions are compensation-related share awards rather than open‑market purchases or sales.
CELIAN JASON reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC Chief Accounting Officer Celian Jason received a stock grant of 6,982 Ordinary Shares on April 22, 2026. The award was recorded at a price of $0.0000 per share, indicating a compensation-related grant rather than an open-market purchase. Following this transaction, Jason directly holds 9,335 Ordinary Shares of Versigent PLC.
Versigent PLC reported that its Chief Financial Officer, Douglas R. Ostermann, received a grant of 43,438 Ordinary Shares as a stock award. The shares were acquired at a reported price of $0.00 per share, indicating a compensation-related grant rather than a market purchase.
Following this award, the CFO directly holds 169,542 Ordinary Shares. This filing reflects an equity-based compensation event and does not show any open-market buying or selling activity.
Liotine Joseph T. reported acquisition or exercise transactions in this Form 4 filing.
Versigent PLC disclosed that CEO and director Joseph T. Liotine received a grant of 111,698 Ordinary Shares on April 22, 2026. The award was recorded at a price of $0.00 per share, indicating it is a compensation-related equity grant rather than an open-market purchase. Following this grant, Liotine directly holds 230,153 Ordinary Shares.
Versigent PLC director Brad M. Cerepak received a grant of 5,168 Ordinary Shares as equity compensation. The shares were acquired on a non-cash basis at a reported price of $0.0000 per share. Following this award, he directly holds 5,168 Ordinary Shares, with no derivative positions reported.